MA49661A - Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 - Google Patents
Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8Info
- Publication number
- MA49661A MA49661A MA049661A MA49661A MA49661A MA 49661 A MA49661 A MA 49661A MA 049661 A MA049661 A MA 049661A MA 49661 A MA49661 A MA 49661A MA 49661 A MA49661 A MA 49661A
- Authority
- MA
- Morocco
- Prior art keywords
- gdf
- inhibitors
- functionality
- increasing resistance
- increasing
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title 1
- 108010056852 Myostatin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562147853P | 2015-04-15 | 2015-04-15 | |
US201562234899P | 2015-09-30 | 2015-09-30 | |
US201562261528P | 2015-12-01 | 2015-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49661A true MA49661A (fr) | 2020-06-03 |
Family
ID=55809250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049661A MA49661A (fr) | 2015-04-15 | 2016-04-15 | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10934349B2 (fr) |
EP (1) | EP3283519A1 (fr) |
JP (1) | JP6877357B2 (fr) |
KR (1) | KR20170135967A (fr) |
CN (1) | CN107771081A (fr) |
AU (1) | AU2016249015B2 (fr) |
CA (1) | CA2982810A1 (fr) |
EA (1) | EA201792298A1 (fr) |
HK (1) | HK1250236A1 (fr) |
IL (1) | IL255010B2 (fr) |
MA (1) | MA49661A (fr) |
MX (1) | MX2017013267A (fr) |
WO (1) | WO2016168613A1 (fr) |
ZA (1) | ZA201707550B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
SI2275443T1 (sl) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
RS56796B1 (sr) | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
TWI766493B (zh) | 2012-08-24 | 2022-06-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
EP3597747B1 (fr) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps fc spécifiques fcgammarii de souris |
WO2014163101A1 (fr) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Variant de région fc |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | 抗プロ/潜在型−ミオスタチン抗体およびその使用 |
KR20180054923A (ko) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
MA49661A (fr) | 2015-04-15 | 2020-06-03 | Regeneron Pharma | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
EP3922645A1 (fr) | 2015-09-15 | 2021-12-15 | Scholar Rock, Inc. | Anticorps anti-pro/myostatine latente et leurs utilisations |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
KR20230028813A (ko) * | 2016-06-13 | 2023-03-02 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
CN111787981A (zh) * | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
AU2019401575A1 (en) * | 2018-12-18 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, GDF8 and Activin A |
CN111303280B (zh) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
US20230390296A1 (en) | 2020-10-30 | 2023-12-07 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1910220A (en) * | 1931-10-21 | 1933-05-23 | Kremser Alois | Mechanically operated gate |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0940468A1 (fr) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Domaine variable d'un anticorps humanisé |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
WO1994021681A1 (fr) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Facteur gde8 de differentiation de croissance |
DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
US6670140B2 (en) | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
CN1829532A (zh) | 2003-06-02 | 2006-09-06 | 惠氏公司 | 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途 |
UA93855C2 (ru) | 2003-12-31 | 2011-03-25 | Шеринг-Плау Лтд. | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе |
AU2005219441A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | ALK7 and myostatin inhibitors and uses thereof |
MXPA06010929A (es) | 2004-03-23 | 2007-01-16 | Lilly Co Eli | Anticuerpos anti-miostatina. |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
JP2008509927A (ja) | 2004-08-12 | 2008-04-03 | ワイス | Gdf−8阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法 |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
AU2006239860B2 (en) | 2005-04-25 | 2012-01-19 | Amgen Fremont Inc. | Antibodies to myostatin |
EP2301969B1 (fr) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | Anticorps monoclonaux IL-31 et procédés d'utilisation |
EP1773041A1 (fr) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Système de transmission de signaux audio/vidéo en utilisant l'Internet pour interconnecter des téléphones |
ES2659114T3 (es) | 2005-08-19 | 2018-03-13 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8 |
KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
MY147468A (en) | 2006-06-02 | 2012-12-14 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
DK2054434T3 (en) | 2006-08-03 | 2017-07-03 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
EA015916B1 (ru) | 2006-09-05 | 2011-12-30 | Эли Лилли Энд Компани | Моноклональные антитела к миостатину и их применения |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
ATE550333T1 (de) | 2007-11-05 | 2012-04-15 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose |
DK3494986T3 (da) | 2008-08-14 | 2020-08-03 | Acceleron Pharma Inc | GDF fanger |
TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
CA2781152A1 (fr) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Proteines actriib et variants et utilisations de celles-ci se rapportant a l'induction de l'utrophine pour une therapie de la dystrophie musculaire |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
SG10201506405YA (en) | 2010-08-16 | 2015-10-29 | Amgen Inc | Polypeptides That Bind Myostatin, Compositions And Methods |
WO2012064771A1 (fr) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Agents de liaison à actriia et leurs utilisations |
CN110124039A (zh) | 2011-05-16 | 2019-08-16 | 建新公司 | 使用甲氨蝶呤诱导免疫耐受性 |
RS56796B1 (sr) | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
JP6433889B2 (ja) | 2012-06-15 | 2018-12-05 | ファイザー・インク | Gdf−8に対する改善された拮抗抗体およびその使用 |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
SG10201706148WA (en) | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
SG10201801063TA (en) * | 2013-08-14 | 2018-04-27 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
MA49661A (fr) | 2015-04-15 | 2020-06-03 | Regeneron Pharma | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
WO2018009732A1 (fr) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-activine a et méthodes d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire |
CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
-
2016
- 2016-04-15 MA MA049661A patent/MA49661A/fr unknown
- 2016-04-15 IL IL255010A patent/IL255010B2/en unknown
- 2016-04-15 CN CN201680035382.9A patent/CN107771081A/zh active Pending
- 2016-04-15 CA CA2982810A patent/CA2982810A1/fr active Pending
- 2016-04-15 MX MX2017013267A patent/MX2017013267A/es unknown
- 2016-04-15 EP EP16718831.7A patent/EP3283519A1/fr active Pending
- 2016-04-15 EA EA201792298A patent/EA201792298A1/ru unknown
- 2016-04-15 AU AU2016249015A patent/AU2016249015B2/en active Active
- 2016-04-15 WO PCT/US2016/027774 patent/WO2016168613A1/fr active Application Filing
- 2016-04-15 KR KR1020177032792A patent/KR20170135967A/ko not_active IP Right Cessation
- 2016-04-15 US US15/099,701 patent/US10934349B2/en active Active
- 2016-04-15 JP JP2017553974A patent/JP6877357B2/ja active Active
-
2017
- 2017-11-08 ZA ZA2017/07550A patent/ZA201707550B/en unknown
-
2018
- 2018-07-25 HK HK18109657.5A patent/HK1250236A1/zh unknown
-
2021
- 2021-01-14 US US17/149,540 patent/US12029788B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018512435A (ja) | 2018-05-17 |
US20210246198A1 (en) | 2021-08-12 |
HK1250236A1 (zh) | 2018-12-07 |
CN107771081A (zh) | 2018-03-06 |
KR20170135967A (ko) | 2017-12-08 |
AU2016249015A1 (en) | 2017-11-09 |
IL255010B2 (en) | 2024-01-01 |
CA2982810A1 (fr) | 2016-10-20 |
WO2016168613A1 (fr) | 2016-10-20 |
AU2016249015B2 (en) | 2022-03-24 |
EP3283519A1 (fr) | 2018-02-21 |
ZA201707550B (en) | 2018-11-28 |
IL255010B1 (en) | 2023-09-01 |
IL255010A0 (en) | 2017-12-31 |
US20160304595A1 (en) | 2016-10-20 |
JP6877357B2 (ja) | 2021-05-26 |
US12029788B2 (en) | 2024-07-09 |
MX2017013267A (es) | 2018-08-15 |
US10934349B2 (en) | 2021-03-02 |
EA201792298A1 (ru) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49661A (fr) | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 | |
DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
KR20180084891A (ko) | 구조 조성물 및 방법 | |
MA41997A (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
BR112016025864A2 (pt) | método de lançamento do aplicativo de terminal e terminal | |
DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
DK3394272T3 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener | |
DK3283210T3 (da) | Fremgangsmåde | |
DK3233071T3 (da) | Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme | |
BR112016025413A2 (pt) | método de fabricação de um inserto e inserto | |
DK3325661T3 (da) | Fgfr-ekspression og følsomhed overfor en fgfr-inhibitor | |
DK3107902T3 (da) | Forbindelser og fremgangsmåder til at hæmme fascin | |
DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
DK3227325T3 (da) | Sammensætninger med selektive hæmmere af il-6-trans-signalering | |
DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
DK3143018T3 (da) | Carboxamidderivater | |
DK3133166T3 (da) | Sammensætning og fremgangsmåde til hybridisering | |
DK3113774T3 (da) | Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf | |
DK3202266T3 (da) | Hæmmer af biologisk korrosion af metaller |